STADA Arzneimittel

Privately held: no public share price

Assets

(6 total)
6Total Assets
3Approved
2Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
BAT1806(Tofidence)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Approved
Glucocorticoid receptorSmall molecule
IgA Nephropathy
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Trigel(Lecigon)
Phase 3
COMTSmall molecule
Parkinson's Disease
Preclinical / Unstaged
VEGF-AProtein / enzyme therapeutic
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026FDA action dateRanibizumab (Ximluci)BsUFA action date for the Ximluci ranibizumab biosimilar BLA (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗
3 June 2026Filing acceptedRanibizumab (Ximluci)FDA accepts the resubmitted BLA for the Ximluci ranibizumab biosimilar (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗

Financial reports

No financial reports recorded.